... comprise injectable GLP-1 receptor agonists and orally active dipeptidyl peptidase-IV inhibitors. Both have a low hypoglycaemia risk. GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, dulaglutide, albiglutide) reduce glycated haemoglobin levels more effectively than oral antidiabetic agents do...

..., Kaufman JM, Ryden M, Muller S, Hanisch FG, Ruige J, Arner P, Sell H, Eckel J: Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60:1917-1925. 9. Sell H, Blüher M, Klöting N, Schlich R, Willems M, Ruppe F, Knoefel W, Dietrich A, Arner P...

... peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012;14:762-767. 3. Kim YG, Hahn S, Oh TJ, et al: Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4...

... of these metabolic functions has led to the notion that incretin hormones, and specifically GLP-1, would represent ideal antidiabetic treatment options. As native GLP-1 is degraded by dipeptidyl peptidase type 4 (DPP-4) within minutes, other pharmacological approaches to exploit GLP-1 actions for the treatment...

... dipeptidyl peptidase-4, visfatin and lipocalin-2. On the other hand, we summarize the most recent findings on the novel cardioprotective adipokines omentin and apelin. In the context of obesity, adipose tissue (AT) has gained considerable interest as a key player in the pathogenesis of several major...

... because the patients' reduced glomerular filtration rate results in the accumulation of certain drugs and/or their metabolites. Although recommended oral antidiabetic agents for patients with CKD differ between countries, all of the currently available dipeptidyl peptidase-4 (DPP-4) inhibitors can be used...

.... In this chapter, we will discuss the potential mechanisms and current understanding of CV and CBV benefits of native glucagon-like peptide (GLP)-1, GLP-1 receptor agonists and analogues, and of dipeptidyl peptidase-4 inhibitor therapies as a means to better understand differences in safety and efficacy...

.... Periodic screening for diabetes after transplantation is recommended for all transplant recipients, and management of hyperglycemia should be intensive and started right after diagnosis. Treatment choices include insulin, metformin, meglitinide derivatives and dipeptidyl peptidase 4 inhibitors...

... hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744. 4. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368...

...: dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic peptide. The DPP-4 inhibitors sitagliptin and vildagliptin are orally active and have been shown to be efficacious and safe. They reduce hemoglobin A1c...

... Abstract Recently we have discovered that the incretin hormone glucagon-like peptide-1 (GLP-2) is an important mediator of cell migration and that GLP-2 is also able to increase proliferation of colon cancer cells. We found that dipeptidyl peptidase IV inhibitors - thought to be a treatment...

... disease. New possibilities are representedby incretin mimetic compounds, dipeptidyl peptidase (DPP)-4 inhibitors, inhaled insulinand eventually oral insulin. ...

... but malabsorptionmay be compounded by inactivation of pancreatic enzymes byhyperacidity and peptidases in the upper intestine, derangedbile salt function, and associated enteropathies. Gastrooesophagealreflux disease is also common but underdiagnosed.Long-standing oesophageal hyperacidity maypredispose...

... from the pancreatoenteric anastomosis has a limitation because GGT is secreted into enteric fluids as well as into pancreatic juice. In order to improve the specificity of fluorescence imaging of pancreatic juice, novel fluorescent probes activated only by pancreas-specific peptidases have been...

... therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012;14:675-688. 4. Monami M, Dicembrini I, Martelli D, Mannucci E: Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(suppl 3):57-64. 5...

... Abstract SummaryKidney tolerance of ifosfamide in combination with mesna was evaluated using 1-day and 5-day regimens by measuring the alanine-amino-peptidase (AAP) and monoclonal antibodies against antigens of defined subregions of the nephron of human kidney with a sandwich ELISA test...